|
Delayed
NYSE
19:45:58 23/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.1707 USD | -3.56% |
|
+3.39% | -70.87% |
| 08-20 | Top Premarket Decliners | MT |
| 08-13 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Matinas BioPharma
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 271.5 | 218.4 | 108.4 | 46.97 | 2.594 | 3.754 |
| Change | - | -19.56% | -50.35% | -56.68% | -94.48% | 44.7% |
| Enterprise Value (EV) 1 | 216.6 | 173.5 | 83.79 | 36.77 | -1.796 | 1.109 |
| Change | - | -19.9% | -51.7% | -56.12% | -104.88% | 161.76% |
| P/E | -11.5x | -8.96x | -5.16x | -2.05x | -0.1x | -0.29x |
| PBR | 4.54x | 4.16x | 2.97x | 2.44x | 0.34x | 0.78x |
| PEG | - | 1.97x | 0.4x | -0.23x | 0.02x | 0x |
| Capitalization / Revenue | 1,715x | 6,552x | 34x | 42.9x | - | - |
| EV / Revenue | 1,368x | 5,205x | 26.3x | 33.6x | - | - |
| EV / EBITDA | -9.06x | -7.09x | -3.46x | -1.57x | 0.09x | -0.16x |
| EV / EBIT | -8.95x | -7.01x | -3.41x | -1.55x | 0.09x | -0.16x |
| EV / FCF | -22.2x | -21x | -5.82x | -5.37x | 0.24x | -0.33x |
| FCF Yield | -4.51% | -4.75% | -17.2% | -18.6% | 415% | -301% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -5.902 | -5.633 | -4.842 | -5.28 | -4.984 | -2.003 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.1583 | 0.0333 | 3.188 | 1.096 | - | - |
| EBITDA 1 | -23.92 | -24.45 | -24.23 | -23.37 | -19.79 | -6.924 |
| EBIT 1 | -24.21 | -24.73 | -24.59 | -23.77 | -20.16 | -6.96 |
| Net income 1 | -22.45 | -23.28 | -21 | -22.94 | -24.25 | -10.34 |
| Net Debt 1 | -54.93 | -44.92 | -24.64 | -10.2 | -4.39 | -2.645 |
| Reference price 2 | 68.0000 | 50.5000 | 25.0000 | 10.8100 | 0.5100 | 0.5860 |
| Nbr of stocks (in thousands) | 3,993 | 4,325 | 4,337 | 4,345 | 5,087 | 6,406 |
| Announcement Date | 29/03/21 | 08/03/22 | 15/03/23 | 27/03/24 | 15/04/25 | 31/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.6M | |
| 21.8x | 7.74x | 15.55x | 1.36% | 74.27B | |
| 31.81x | 9.18x | 28.6x | 0.04% | 61.21B | |
| 31.83x | 6.79x | 17.62x | -.--% | 27.55B | |
| -73.75x | 14.26x | -68.76x | -.--% | 26.38B | |
| -15.46x | 5.96x | -7.5x | -.--% | 25.34B | |
| 28.48x | 5.36x | 17.82x | -.--% | 20.84B | |
| 1066.25x | 37.33x | 644.76x | -.--% | 14.94B | |
| 43.75x | 16.03x | 32.53x | 0.34% | 15.17B | |
| 17.96x | 5.35x | 12.5x | -.--% | 14.41B | |
| Average | 128.07x | 12.00x | 77.01x | 0.19% | 28.01B | |
| Weighted average by Cap. | 69.79x | 10.14x | 43.06x | 0.39% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MTNB Stock
- Valuation Matinas BioPharma
Select your edition
All financial news and data tailored to specific country editions
